BCYC
Bicycle Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$4.30
+1.42%Aug 20, 2026, 00:00 UTC
Charles Swanton resigned as Class II director of Bicycle Therapeutics PLC's Board of Directors, effective August 18, 2026.
Jul 30, 2026, 00:00 UTC
Bicycle Therapeutics PLC reported financial results for the second quarter of 2026, with collaboration revenue of $629,000 and a net loss of $50.3 million.